A new automated robotic line costing more than €6 million has enabled Cristalmina to increase production from 2.5 million to 15 million units per year By 2021, the company plans to have authorisation to market Cristalmina in more than 26 European countries, which will be followed by Asia and the USA in the years to […]
Salvat’s News and Press kit
Salvat at a glance
What are we doing right now
Again this year, Laboratorios Salvat, S.A. has been granted with the rating “VERY GOOD” by the PROFARMA 2019 program of the Spanish Ministry of Industry, which values pharmaceutical companies based on their excellence in Industrial, economic and Research, Development and Innovation activities. This qualification represents an important recognition of Salvat’s continued efforts towards its objective […]
The research, currently underway both in the United States of America and Europe, will involve an investment of more than $10 million. The worldwide launch of the new medicament to treat this type of external otitis, expected for the end of 2021, reinforces Salvat’s positioning in otology at an international level. The company’s international business […]
Japanese companies from the pharmaceutical sector visit Pharmaloop’s facilities (a Salvat company) through @ICEX and @IcexJapon.
On the 5th, 6th and 7th of November, the city of Frankfurt hosted one of the largest events worldwide in the pharmaceutical industry, bringing together over 45,000 visiting attendees and 2,500 international exhibitors: CPhI Worldwide 2019. Salvat and Pharmaloop teams held numerous meetings with current and potential partners from all over the world of the […]